Effet of immune modulation in relapsed peripheral T-cell lymphomas after allogeneic stem cell transplantation: a study by the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC)
[en] Peripheral T-cell lymphoma carries a poor prognosis. To document a possible graft-versus-lymphoma effect in this setting, we evaluated the impact of immunomodulation in 63 patients with peripheral T-cell lymphoma who relapsed after allogeneic transplant in 27 SFGM-TC centers. Relapse occurred after a median of 2.8 months. Patients were then treated with nonimmunologic
strategies (chemotherapy, radiotherapy) and/or immune modulation (donor lymphocyte infusions (DLI) and/or discontinuation of immunosuppressive therapy). Median overall survival (OS) after relapse was 6.1 months (DLI group: 23.6 months, non-DLI group: 3.6 months). Among the 14 patients who received DLI, 9 responded and 2 had stable disease. Among the remaining
49 patients, a complete response accompanied by extensive chronic GvHD was achieved in two patients after tapering of immunosuppressive drugs. Thirty patients received radio-chemotherapy, with an overall response rate of 50%. In multivariate analysis, chronic GvHD (odds ratio: 11.25 (2.68–48.21), P = 0.0009) and skin relapse (odds ratio: 4.15 (1.04–16.50), P = 0.043) were associated with a better response to treatment at relapse. In a time-dependent analysis, the only factor predictive of OS was the time from transplantation to relapse (hazards ratio: 0.33 (0.17–0.640), P = 0.0009). This large series provides encouraging evidence of a true GvL effect in this disease.
Disciplines :
Hematology
Author, co-author :
Mamez
Levy, V
Chevallier, P
Blaise, D
Vigouroux, S
Xhaard, A
Fegueux, N
Contentin, N
BEGUIN, Yves ; Centre Hospitalier Universitaire de Liège - CHU > Service d'hématologie clinique
Effet of immune modulation in relapsed peripheral T-cell lymphomas after allogeneic stem cell transplantation: a study by the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC)
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Bibliography
Abouyabis AN, Shenoy PJ, Sinha R, Flowers CR, Lechowicz MJ. A systematic review and meta-analysis of front-line anthracycline-based chemotherapy regimens for peripheral T-cell lymphoma. ISRN Hematol 2011; 2011: 623924.
Reimer P, Rüdiger T, Geissinger E, Weissinger F, Nerl C, Schmitz N et al. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol 2009; 27: 106-113.
Kyriakou C, Canals C, Finke J, Kobbe G, Harousseau J-L, Kolb H-J et al. Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: a retrospective study from the lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol 2009; 27: 3951-3958.
Gouill SL, Milpied N, Buzyn A, Latour RPD, Vernant J-P, Mohty M et al. Graft-versuslymphoma effect for aggressive t-cell lymphomas in adults: a study by the Société Française De Greffe De Mo?lle et De Thérapie Cellulaire. J Clin Oncol 2008; 26: 2264-2271.
Dodero A, Spina F, Narni F, Patriarca F, Cavattoni I, Benedetti F et al. Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect. Leukemia 2012; 26: 520-526.
Goldberg JD, Chou JF, Horwitz S, Teruya-Feldstein J, Barker JN, Boulad F et al. Long-term survival in patients with peripheral T-cell non-Hodgkin lymphomas after allogeneic hematopoietic stem cell transplant. Leuk Lymphoma 2012; 53: 1124-1129.
Duarte RF, Canals C, Onida F, Gabriel IH, Arranz R, Arcese W et al. Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sézary syndrome: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2010; 28: 4492-4499.
Jacobsen ED, Kim HT, Ho VT, Cutler CS, Koreth J, Fisher DC et al. A large singlecenter experience with allogeneic stem-cell transplantation for peripheral T-cell non-Hodgkin lymphoma and advanced mycosis fungoides/Sezary syndrome. Ann Oncol 2011; 22: 1608-1613.
Zain J, Palmer JM, Delioukina M, Thomas S, Tsai N-C, Nademanee A et al. Allogeneic hematopoietic cell transplant for peripheral T-cell non-Hodgkin lymphoma results in long-term disease control. Leuk Lymphoma 2011; 52: 1463-1473.
Loirat M, Chevallier P, Leux C, Moreau A, Bossard C, Guillaume T et al. Upfront allogeneic-stem cell transplantation for patients with non-localized untreated peripheral T-cell lymphoma: an intention-to-treat analysis from a single center. Ann Oncol 2014; 26: 386-392.
Robles M, Vigouroux S, Tabrizi R, Bouabdallah K, Dilhuydy M-S, Parrens M et al. Allogeneic SCT for patients with high-risk peripheral T-cell lymphoma in first response. Bone Marrow Transplant 2013; 48: 1484-1485.
Corradini P, Dodero A, Zallio F, Caracciolo D, Casini M, Bregni M et al. Graft-versuslymphoma effect in relapsed peripheral T-cell non-Hodgkin?s lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol 2004; 22: 2172-2176.
Itonaga H, Tsushima H, Taguchi J, Fukushima T, Taniguchi H, Sato S et al. Treatment of relapsed adult T-cell leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation: the Nagasaki Transplant Group experience. Blood 2013; 121: 219-225.
Kanakry JA, Kasamon YL, Gocke CD, Tsai H-L, Davis-Sproul J, Ghosh N et al. Outcomes of related donor HLA-identical or HLA-haploidentical allogeneic blood or marrow transplantation for peripheral T cell lymphoma. Biol Blood Marrow Transplant 2013; 19: 602-606.
Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825-828.
Mamez AC, Souchet L, Roos-Weil D, Uzunov M, Brun AL, Algrin C et al. Graftversus-T-cell lymphoma effect: a sustained CR after tapering immunosuppressive drugs in a patient with angioimmunoblastic T-cell lymphoma in relapse after allogeneic transplantation. Bone Marrow Transplant 2014; 50: 304-306.
Molina A, Zain J, Arber DA, Angelopolou M, O?Donnell M, Murata-Collins J et al. Durable clinical, cytogenetic, and molecular remissions after allogeneic hematopoietic cell transplantation for refractory Sezary syndrome and mycosis fungoides. J Clin Oncol 2005; 23: 6163-6171.
Yuan L, Sun L, Bo J, Zhou Y, Li H, Yu L et al. Durable remission in a patient with refractory subcutaneous panniculitis-like T-cell lymphoma relapse after allogeneic hematopoietic stem cell transplantation through withdrawal of cyclosporine. Ann Transplant 2011; 16: 135-138.
Kako S, Izutsu K, Oshima K, Sato H, Kanda Y, Motokura T et al. Regression of the tumor after withdrawal of cyclosporine in relapsed extranodal natural killer/T cell lymphoma following allogeneic hematopoietic stem cell transplantation. Am J Hematol 2007; 82: 937-939.
Chakraverty R, Mackinnon S. Allogeneic transplantation for lymphoma. J Clin Oncol 2011; 29: 1855-1863.
Schetelig J, Thiede C, Bornhauser M, Schwerdtfeger R, Kiehl M, Beyer J et al. Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group. J Clin Oncol 2003; 21: 2747-2753.
Horwitz SM, Advani RH, Bartlett NL, Jacobsen ED, Sharman JP, O?Connor OA et al. Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Blood 2014; 123: 3095-3100.
This website uses cookies to improve user experience. Read more
Save & Close
Accept all
Decline all
Show detailsHide details
Cookie declaration
About cookies
Strictly necessary
Performance
Strictly necessary cookies allow core website functionality such as user login and account management. The website cannot be used properly without strictly necessary cookies.
This cookie is used by Cookie-Script.com service to remember visitor cookie consent preferences. It is necessary for Cookie-Script.com cookie banner to work properly.
Performance cookies are used to see how visitors use the website, eg. analytics cookies. Those cookies cannot be used to directly identify a certain visitor.
Used to store the attribution information, the referrer initially used to visit the website
Cookies are small text files that are placed on your computer by websites that you visit. Websites use cookies to help users navigate efficiently and perform certain functions. Cookies that are required for the website to operate properly are allowed to be set without your permission. All other cookies need to be approved before they can be set in the browser.
You can change your consent to cookie usage at any time on our Privacy Policy page.